Garber Alan M, a director at Vertex Pharmaceuticals, has reported the acquisition of 29.272 deferred stock units as of October 15, 2026. This move is significant as it indicates Garber's ongoing confidence in the company and its future prospects.
Vertex Pharmaceuticals, based in Boston, Massachusetts, is known for its focus on developing innovative therapies, particularly in the field of cystic fibrosis and other serious diseases. The company is classified under the SIC code for Pharmaceutical Preparations.
According to the recent filing, Garber's transaction involved acquiring the deferred stock units at a price of $512.44 per share. Following this transaction, Garber now holds a total of 94.73 shares of Vertex common stock. The filing notes that each deferred stock unit represents one share of common stock, which will be paid out upon specific conditions such as termination of service or a change of control.
This acquisition could have implications for shareholder sentiment, as Garber's actions may be seen as a vote of confidence in Vertex's strategic direction. As a director, his stake in the company could influence decision-making processes and overall company governance.
The filing does not say what happens next regarding further transactions or company developments.
Details of the Transaction
The acquisition of the deferred stock units was reported under Form 4, which is used to disclose changes in the ownership of securities by corporate insiders. The transaction was coded as 'A', indicating an acquisition of securities. The filing specifies that the deferred stock units were acquired at a price of $512.44 per share, reflecting the market value at the time of the transaction.
Garber's total holdings now include 94.73 shares of Vertex common stock, which demonstrates his significant stake in the company. The filing also clarifies that the deferred stock units will convert into common stock under specific circumstances, including termination of service, a change of control, or in the event of Garber's disability or death.
Company Overview
Vertex Pharmaceuticals is a prominent player in the biotech sector, particularly noted for its innovative approaches to treating cystic fibrosis. The company operates under the SIC code for Pharmaceutical Preparations and is headquartered in Boston, Massachusetts. Vertex's commitment to developing therapies for serious diseases positions it as a key entity in the life sciences industry.
"Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Dr. Garber's service on our board of directors, (ii) a change of control of our company and (iii) Dr. Garber's disability or death."
While the filing provides detailed information about Garber's recent acquisition, it does not include any insights into future transactions or strategic initiatives that Vertex Pharmaceuticals may undertake.